ABF Pharmaceutical Services GmbH (part of GBA Group Pharma) is a Viennese company founded in 2004, specializing in all aspects of international clinical trials, including project management, manufacturing, logistics and EU approval of investigational medicinal products, as well as import, storage and logistics for approved pharmaceuticals. ABF has a total area of 2,750 square metres (production and warehouse 1,580 m2 and office 1,170m2). State-of-theart processing facilities offer 1,089 pallet spaces (948 spaces at room temperature/ 141 for cold storage), 5 packaging rooms (primary packaging/ secondary packaging/ cold chain) and a GMP warehouse for investigational medicinal products and commercial goods. In 2016, ABF became a member of GBA Group Pharma, one of Europe's largest and most experienced service groups in the pharmaceutical and biotech sector. With its preclinical services, analytical test laboratories and international central laboratory, the company generates annual sales of around 50 million euros.

Der Schutz vor Lebensmittelfälschungen stellt angesichts der aktuellen Situation eine Herausforderung dar.
Aufgrund von Abweichungen in der Routine von globalen Lieferketten und der amtlichen Überwachung besteht ein erhöhtes Risiko des Lebensmittelbetrugs.

Wie können Sie für Schutz vor Betrug, Sicherheit und Integrität ihrer Lebensmittel sorgen?

Unser Head of Sales der GBA Group, Dr. Markus Zell, gibt in einem Podcast des Fruchthandel Magazins Einblicke zur aktuellen Situation der Labore in der Corona Krise.

Press Article

Laboratorium für Klinische Forschung, a member of GBA Group Pharma, is offering an analytical method for detecting SARS-CoV-2 from nasopharyngeal swabs. This has enabled the company to significantly expand its existing range of COVID-19 testing methods for clinical trials. Based on a Roche LightCycler 480 II, which uses the technique of real-time PCR (polymerase chain reaction), LKF can now perform numerous molecular biological applications (DNA or RNA analyses). The detection of the RNA of the SARS-CoV-2 virus is a prerequisite for the diagnosis of an acute infection with the new corona virus causing the disease COVID-19.

published in LABMATE on the 1st June 2020

Elisabeth Lackner, CEO ABF Pharmaceutical Services und GBA GroupPharma, im Interview über Beschleunigungen in der Zulassung, Engpässe bei benötigten Medikamenten und ethische Grundsätze

ABF unterstützt derzeit mehrere klinische Covid- 19 Studien – insgesamt wickelt ABF derzeit mehr als 120 klinische Studien ab. LEADERSNET hat Elisabeth Lackner, CEO der ABF Pharmaceutical Services und GBA GROUP Pharma, zum Interview getroffen.

veröffentlicht in OPINION LEADERS NETWORK am 20.5.2020